1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > EpiCast Report: Glaucoma - Epidemiology Forecast to 2023

EpiCast Report: Glaucoma - Epidemiology Forecast to 2023

Summary

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye’s optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. Glaucoma is generally categorized as open-angle glaucoma (OAG), angle-closure glaucoma (ACG), secondary glaucoma, and congenital glaucoma. Other less common types of glaucoma include normal-tension glaucoma (NTG), pseudoexfoliation glaucoma, and pigmentary glaucoma (NEI, 2014b). Although there are many types of glaucoma, the two most important types are OAG and ACG, with OAG accounting for about 80-90% of all glaucoma cases (Mayo Clinic, 2014). OAG and ACG can be primary (primary open-angle glaucoma [POAG] and primary angle-closure glaucoma [PACG], respectively) or secondary, depending on the cause.

GlobalData epidemiologists forecast that the total prevalent cases of glaucoma in the 7MM will grow by 14.60% over the next decade, from 13,748,430 total prevalent cases in 2013 to 15,761,674 total prevalent cases in 2023, with almost 60% of the total prevalent cases occurring in the US and Japan together.

The increase in the number of total prevalent cases of glaucoma in the 7MM can be attributed to changing population demographics in the respective markets. However, further epidemiological research is warranted given that there is a paucity of national and international data evaluating the prevalence and trends of glaucoma worldwide. There is also a need to clearly demarcate the glaucoma population in each clinical type, as currently available epidemiological literature fails to clearly demarcate different glaucoma populations.

Scope

- The Glaucoma EpiCast Report provides an overview of the risk factors and global trends of glaucoma in the 7MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of total prevalent cases of glaucoma segmented by age (in five-year increments beginning at age 40), sex, clinical type (POAG, PACG, secondary glaucoma, and congenital glaucoma the total prevalent cases of NTG, which is a sub-type of OAG; and the diagnosed prevalent cases of POAG and PACG in these markets.
- The glaucoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global glaucoma market.
- Quantify patient populations in the global glaucoma market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for glaucoma therapeutics in each of the markets covered.
- Identify the percentage of glaucoma prevalent cases by clinical type.

Table Of Contents

EpiCast Report: Glaucoma - Epidemiology Forecast to 2023
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 13
3.3.1 US 13
3.3.2 5EU 14
3.3.3 Japan 15
3.4 Forecast Methodology 16
3.4.1 Sources Used 18
3.4.2 Forecast Assumptions and Methods 22
3.4.3 Sources Not Used 28
3.5 Epidemiological Forecast for Glaucoma (2013-2023) 29
3.5.1 Total Prevalent Cases of Glaucoma 29
3.5.2 Age-Specific Total Prevalent Cases of Glaucoma 30
3.5.3 Sex-Specific Total Prevalent Cases of Glaucoma 32
3.5.4 Age-Standardized Total Prevalence of Glaucoma 34
3.5.5 Total Prevalent Cases of Glaucoma, by Clinical Type 35
3.5.6 Total Prevalent Cases of NTG 37
3.5.7 Diagnosed Prevalent Cases of POAG and PACG 39
3.6 Discussion 42
3.6.1 Epidemiological Forecast Insight 42
3.6.2 Limitations of the Analysis 43
3.6.3 Strengths of the Analysis 44
4 Appendix 45
4.1 Bibliography 45
4.2 About the Authors 48
4.2.1 Epidemiologists 48
4.2.2 Reviewers 48
4.2.3 Global Director of Therapy Analysis and Epidemiology 49
4.2.4 Global Head of Healthcare 50
4.3 About GlobalData 51
4.4 About EpiCast 51
4.5 Disclaimer 51

1.1 List of Tables
Table 1: Types of Glaucoma 10
Table 2: Risk Factors and Comorbidities for Glaucoma 12
Table 3: 7MM, Sources of Glaucoma Total Prevalence Data Used in the Epidemiology Forecast 17
Table 4: 7MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of Glaucoma Segmented by Clinical Types 18
Table 5: 7MM, Sources Not Used in the Epidemiological Analysis of Glaucoma 28
Table 6: 7MM, Total Prevalent Cases of Glaucoma, Ages ?40 Years, Both Sexes, N, 2013-2023 29
Table 7: 7MM, Total Prevalent Cases of Glaucoma, by Age, Both Sexes, N (Row %), 2013 31
Table 8: 7MM, Total Prevalent Cases of Glaucoma, by Sex, Ages ?40 Years, N (Row %), 2013 33
Table 9: 7MM, Total Prevalent Cases of Glaucoma, by Clinical Type, Ages ?40 Years, N (Row %), 2013 36
Table 10: 7MM, Total Prevalent Cases of NTG, Ages ?40 Years, Both Sexes, N, 2013-2023 38
Table 11: 7MM, Diagnosed Prevalent Cases of POAG, Ages ?40 Years, Both Sexes, N, 2013-2023 39
Table 12: 7MM, Diagnosed Prevalent Cases of PACG, Ages ?40 Years, Both Sexes, N, 2013-2023 41

1.2 List of Figures
Figure 1: 7MM, Total Prevalent Cases of Glaucoma, Ages ?40 Years, Both Sexes, N, 2013-2023 30
Figure 2: 7MM, Total Prevalent Cases of Glaucoma, by Age, Both Sexes, N, 2013-2023 32
Figure 3: 7MM, Total Prevalent Cases of Glaucoma, by Sex, Ages ?40 Years, N, 2013 34
Figure 4: 7MM, Age-Standardized Total Prevalence of Glaucoma, by Sex, Ages ?40 Years, %, 2013 35
Figure 5: 7MM, Total Prevalent Cases of Glaucoma, by Clinical Type, Ages ?40 Years, N, 2013 37
Figure 6: 7MM, Total Prevalent Cases of NTG, Ages ?40 Years, Both Sexes, N, 2013-2023 38
Figure 7: 7MM, Diagnosed Prevalent Cases of POAG, Ages ?40 Years, Both Sexes, N, 2013-2023 40
Figure 8: 7MM, Diagnosed Prevalent Cases of PACG, Ages ?40 Years, Both Sexes, N, 2013-2023 41

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Europe Market Report for Fundus Cameras 2017 - MedCore

Europe Market Report for Fundus Cameras 2017 - MedCore

  • $ 6495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description General Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapte ...

Europe Market Report for Slit Lamps 2017 - MedCore

Europe Market Report for Slit Lamps 2017 - MedCore

  • $ 5995
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description General Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapte ...

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Glaucoma Therapeutics Market: Overview Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.